Ropinirole

Base Information

• Chemical Name: Ropinirole
• CAS No.: 91374-21-9
• Molecular Formula: C16H24N2O
• Molecular Weight: 260.379
• European Community (EC) Number: 618-737-7
• NSC Number: 758917
• UNII: 030PYR8953
• DSSTox Substance ID: DTXSID8045195
• Nikkaji Number: J264.965I
• Wikipedia: Ropinirole
• Wikidata: Q420590
• NCI Thesaurus Code: C61931
• RXCUI: 72302
• Pharos Ligand ID: JNR2VS8S2R39
• Metabolomics Workbench ID: 42663
• ChEMBL ID: CHEMBL589
• Mol file: 91374-21-9.mol

Synonyms:4-(2-(di-n-propylamino)ethyl)-2(3H)-indolone;Requip;ropinirol;ropinirole;ropinirole hydrochloride;SK and F 101468;SK and F-101,468;SKF 101468

Chemical Property of Ropinirole

Chemical Property:

• Appearance/Colour: White or yellowish crystalline powder
• Vapor Pressure: 6.01E-07mmHg at 25°C
• Melting Point: 243-250 °C
• Refractive Index: 1.538
• Boiling Point: 410.5 °C at 760 mmHg
• PKA: 14.17±0.20(Predicted)
• Flash Point: 202 °C
• PSA: 32.34000
• Density: 1.04 g/cm³
• LogP: 2.98370
• XLogP3: 2.7
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 2
• Rotatable Bond Count: 7
• Exact Mass: 260.188863393
• Heavy Atom Count: 19
• Complexity: 287

Purity/Quality:

99% ^*data from raw suppliers

Ropinirole ≥99%(HPLC) ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Drug Classes: Antiparkinson Agents
• Canonical SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
• Recent ClinicalTrials: Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis
• Recent EU Clinical Trials: TARGETING DOPAMINE TO TREAT IMPAIRED MEMORY CONSOLIDATION IN NEURODEGENERATIVE DISEASE: A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
• Recent NIPH Clinical Trials: Comparative study of ropinirole and entacapone for the treatment of wearing-off in advanced Parkinson's disease patients
• Uses: Antiparkinsonian (D2receptor agonist).
• Clinical Use: Anti-Parkinson agent Restless legs syndrome (RLS)
• Drug interactions: Potentially hazardous interactions with other drugs Antipsychotics: antagonism of anti-Parkinsonian effect - avoid. Metoclopramide: antagonism of anti-Parkinsonian effect - avoid. Oestrogens: concentration increased.

Technology Process of Ropinirole

There total 56 articles about Ropinirole which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 94.0%

ropinirole hydrochloride (91374-20-8) → Ropinirole (91374-21-9)

Guidance literature:

With sodium hydroxide; In water; at 20 ℃; for 0.25h;

DOI:10.1039/c4md00066h

Reference yield: 81.0%

4-<2-(N,N-di-n-propylamino)ethyl>indole (76149-15-0) → Ropinirole (91374-21-9)

Guidance literature:

4-<2-(N,N-di-n-propylamino)ethyl>indole; With pyridinium hydrobromide perbromide; acetic acid; In water; at 20 - 50 ℃; for 19h;

With sodium hydroxide; In water;

Reference yield: 78.0%

<2-nitro-6-<2-(N,N-di-n-propylamino)ethyl>phenyl>acetic acid hydrochloride (91374-25-3) → Ropinirole (91374-21-9)

Guidance literature:

With hydrogen; palladium on activated charcoal; In ethanol; for 5h; under 2585.7 Torr; Ambient temperature;

DOI:10.1021/jm00148a028

upstream raw materials:

<2-nitro-6-<2-(N,N-di-n-propylamino)ethyl>phenyl>acetic acid hydrochloride

di-n-propylamine

4-(2'-bromoethyl)-1,3-dihydro-2H-indol-2-one

2-(2-oxo-2,3-dihydro-1H-indol-4-yl)ethyl methanesulfonate

Downstream raw materials:

ropinirole hydrochloride

Refernces

• 1、 -. "Method for preparing ropinirole hydrochloride". . . Retrieved 2018/09/12.
• 2、 J?rg, Manuela,May, Lauren T.,Mak, Frankie S.,Lee, Kiew Ching K.,Miller, Neil D.,Scammells, Peter J.,Capuano, Ben. "Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of parkinsons disease". supporting information. p. 718 - 738. Retrieved 2015/01/30.